AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05568173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scapular Stabilization
Description: In addition to scapular stabilization training, stretching exercises and posture training will be given in SSG. Progressive strengthening training for the scapular muscles will be used in the SSG. There will be four difficulty levels. The complexity of the exercises will increase at 2-week intervals as the patient progresses. As a result, 0-2 weeks 1st level, 2-4 weeks 2nd level, 4-6 weeks 3rd level and 6-8 weeks 4th level exercises will be done.~At the first level, scapular clock exercise, obstacle crossing exercise, wall gliding exercise with teraband, push up exercise, trunk rotation and maximum hip flexion will be performed. Then at levels 2-4, as the levels increase, the exercises at the first level will be more difficult (ball weight, surface, number of hurdles and hurdle crossing exercise position, by changing the teraband elasticity, push-up position). In SSG, 3 sessions of 30-minute scapular stabilization training will be applied per week for 8 weeks.
Study NCT06391346 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MSOT
Description: Non-invasive transcutaneous imaging of muscle components via infrared and near-infrared laser pulses
Study NCT06393543 — intervention group
Intervention type: OTHER
Intervention: No intervention, only registration
Description: No intervention, only registration
Study NCT06313827 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise plus Monitoring Group (TG-2)
Description: Participants will receive their usual physiotherapy treatment and user education on bronchial care and hygiene, plus a dossier on the use of monitoring equipment such as: pulse oximeter, thermometer, digital spirometer, Medical Research Council dyspnoea scale. If the patient detects an exacerbation (due to symptoms or monitoring of the equipment), they can contact a physiotherapist who can adjust the treatment.
Study NCT06313827 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise plus monitoring and follow-up group (TGF-3)
Description: Participants who will receive their usual physiotherapy treatment and user education on bronchial care and hygiene, plus dossiers on the use of monitoring equipment ; plus telematic control of exacerbations (questionnaires and monitoring of the parameters of the aforementioned equipment). Depending on the follow-up, physiotherapy treatment will be adjusted.~The questionnaire includes tracking of the following parameters: cough, secretions (quantity, colour, viscosity), chest tightness, dyspnoea, exercise tolerance, tiredness and appetite).~The follow-up will consist of weekly filling the spreadsheet to which the physiotherapist will have access and who, by reviewing the parameters, will be able to adjust the treatment. The physiotherapist will systematically make videocalls to the participants and if the follow-up values require it, he/she will call every week.
Study NCT06313827 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Group (CG-1)
Description: Participants who will receive their usual physiotherapy treatment and user education on bronchial care and hygiene
Study NCT05805930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: : Patients will continue daily treatment with anakinra up to week 12. Treatment will be then progressively tapered through the reduction of an administration of the drug per week. Reductions will be performed every 2 weeks up to discontinuation. Therefore, if a relapse does not occur, the treatment will be withdrawn at week 24.
Study NCT05805930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Steroids will be progressively tapered with a reduction of 0,1-0,15 mg/kg/day of prednisone (or 5 mg in patients in treatment with the maximum dosage of 50 mg/day) from the ongoing treatment every week up to discontinuation. If a relapse does not occur, the treatment will be withdrawn in a period of time of 10 weeks.
Study NCT04542304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metolazone
Description: Participants will be given a metolazone for the 1-week study period.
Study NCT04542304 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be given a placebo for the 1-week study period.
Study NCT06685770 — intervention group
Intervention type: OTHER
Intervention: Mini-cog test
Description: Breast cancer is a very common and important disease in the female population around the world. Anesthesia management during surgery for this disease in the postoperative period should be carefully planned. It will be important to examine the neurocognitive effects of anesthesia management in the postoperative period in this patient group. Today, inhaler and total intravenous anesthesia have advantages as well as disadvantages. It would be valuable to examine its neurocognitive effects in this patient group. In this study, the frequently used Mini-cog test will be used.With Mini-cog test, the patient is asked a number of simple questions to evaluate cognitive functions and each question has certain points. Changes in these score levels preoperatively and postoperatively will be compared within each patient. At the end of the study, preoperative and postoperative changes will be compared statistically between the groups.
Study NCT06690840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab in combination with Cyclophosphamide and Vinorelbine
Description: Patients will receive Atezolizumab in combination with Cyclophosphamide and Vinorelbine in 28-day cycles
Study NCT06691360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK137
Description: IV infusion, specified dose on specified days.
Study NCT06690255 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pivotal Response Treatment
Description: PRT will target functional communication abilities
Study NCT06691178 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Description: The OCT device with cover will be used to take measurements at four areas in the vaginal canal: the proximal posterior aspect, proximal anterior, distal anterior, and distal posterior. The proximal and distal points will be marked on the OCT cover during the first set of measurements. Markings will be used to guide measurements during subsequent visits.
Study NCT06691178 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Optical coherence tomography (OCT)
Description: The OCT device with cover will be used to take measurements at four areas in the vaginal canal: the proximal posterior aspect, proximal anterior, distal anterior, and distal posterior. The proximal and distal points will be marked on the OCT cover during the first set of measurements. Markings will be used to guide measurements during subsequent visits.
Study NCT05857943 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AEYE-DS Software
Description: Eligible participants will undergo the following procedures: Photographic imaging of each eye using a funduscopy camera device. Images obtained will be sent to the AEYE-DS software for analysis. -Additional photographic and OCT images will be obtained using a second funduscopy/OCT camera device. Images obtained will be sent to a professional reading center for analysis. -All study subjects will have their pupils dilated using dilation drops.
Study NCT06253325 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measuring tissue oxygenation
Description: Measuring oxygen content of arteries, capillaries and veins
Study NCT06253325 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Procalcitonin
Description: Blood test
Study NCT06253325 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Mid-regional proadrenomedullin
Description: Blood test looking at inflammation in the body
Study NCT06253325 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hand-held video microscope
Description: A handheld video microscope that looks at blood flow through the capillaries of the tongue
Study NCT04642053 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dynamic Temporal and Tactile Cuing
Description: Dynamic Temporal and Tactile Cuing is based on principles of integral stimulation where the client watches, listens to and imitates the clinician (Strand, 2020). Treatment will begin by training the child to imitate and simultaneously produce syllables/words with the clinician. Sessions will focus on establishing accurate movement transitions in treated words. The child will be asked to imitate the clinician's production of the target. If the child's imitation is inaccurate, they will be instructed to simultaneously produce the target with the clinician. Simultaneous productions will continue to provide practice opportunity with maximal cuing. As the child gains greater accuracy, simultaneous productions will be faded and direct imitation will be attempted again. Over the course of treatment, the movement gesture will be shaped with the goal being accurate production with normal rate and naturalness.
Study NCT04676802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAID capsules
Description: 1, Ibuprofen 400-mg and 1, Acetaminophen 500-mg capsule per dosage
Study NCT04676802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid capsule
Description: 1, Oxycodone 5-mg capsule and 1, placebo capsule per dosage
Study NCT04947501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administration of CTV - cycles 1 and 4~Days 1 \& 2: Cyclophosphamide 70 mg/kg/day (2100 mg/m2/day for patients >10 years old), IV over 6 hrs.~Mesna 70 mg/kg (2100 mg/m2/day for patients >10 years old) , by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Days 1-4: Topotecan 2 mg/m2/day, IV over 30 minutes. Day 1: Vincristine 0.067 mg/kg (or 2 mg/m2, whichever is less) by IV piggyback; maximum dose is 2 mg.~\*\*\*\*\*\*\* Administration of CDV - cycle 3 Days 1 \& 2: Cyclophosphamide 70 mg/kg/day ((2100 mg/m2/day for patients >10 years old), IV over 6 hrs.~Mesna 70 mg/kg ((2100 mg/m2/day for patients >10 years old), by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Days 1-3: Doxorubicin 25 mg/m2/day, by 24-hr IV infusion (total dose over 72 hr is 75 mg/m2).~Days 1-3: Vincristine 0.67 mg/m2/day or 0.022 mg/kg/day (whichever is less), by 24-hr IV infusion (total dose over 72 hr is 2 mg/m2 or 0.067 mg/kg); maximum dose is 0.67 mg/day, or 2mg over 72 hr.
Study NCT04947501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Administration of CTV - cycles 1 and 4~Days 1 \& 2: Cyclophosphamide 70 mg/kg/day (2100 mg/m2/day for patients >10 years old), IV over 6 hrs.~Mesna 70 mg/kg (2100 mg/m2/day for patients >10 years old) , by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Days 1-4: Topotecan 2 mg/m2/day, IV over 30 minutes. Day 1: Vincristine 0.067 mg/kg (or 2 mg/m2, whichever is less) by IV piggyback; maximum dose is 2 mg.
Study NCT04947501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Administration of CTV - cycles 1 and 4~Days 1 \& 2: Cyclophosphamide 70 mg/kg/day (2100 mg/m2/day for patients >10 years old), IV over 6 hrs.~Mesna 70 mg/kg (2100 mg/m2/day for patients >10 years old) , by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Days 1-4: Topotecan 2 mg/m2/day, IV over 30 minutes. Day 1: Vincristine 0.067 mg/kg (or 2 mg/m2, whichever is less) by IV piggyback; maximum dose is 2 mg.
Study NCT04947501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Administration of CDV - cycle 3 Days 1 \& 2: Cyclophosphamide 70 mg/kg/day ((2100 mg/m2/day for patients >10 years old), IV over 6 hrs.~Mesna 70 mg/kg ((2100 mg/m2/day for patients >10 years old), by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Days 1-3: Doxorubicin 25 mg/m2/day, by 24-hr IV infusion (total dose over 72 hr is 75 mg/m2).~Days 1-3: Vincristine 0.67 mg/m2/day or 0.022 mg/kg/day (whichever is less), by 24-hr IV infusion (total dose over 72 hr is 2 mg/m2 or 0.067 mg/kg); maximum dose is 0.67 mg/day, or 2mg over 72 hr.
Study NCT04947501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Administration of ICE - cycle 2 Days 1-5: Ifosfamide 1500 mg/m2/day (50 mg/kg/day if weight is \<10 kg), IV over 6 hrs. Mesna 1500 mg/m2/day, by 24-hr IV infusion, starting with the ifosfamide infusion. Days 1-2: Carboplatin 400 mg/m2/day (13.3 mg/kg/day if weight is \<10 kg), IV over 1 hr. Days 1-5: Etoposide 100 mg/m2/day (3.3. mg/kg/day if weight is \<10 kg), IV over 2 hrs.
Study NCT04947501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Administration of ICE - cycle 2~Days 1-5: Ifosfamide 1500 mg/m2/day (50 mg/kg/day if weight is \<10 kg), IV over 6 hrs. Mesna 1500 mg/m2/day, by 24-hr IV infusion, starting with the ifosfamide infusion. Days 1-2: Carboplatin 400 mg/m2/day (13.3 mg/kg/day if weight is \<10 kg), IV over 1 hr. Days 1-5: Etoposide 100 mg/m2/day (3.3. mg/kg/day if weight is \<10 kg), IV over 2 hrs.
Study NCT04947501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administration of ICE - cycle 2~Days 1-5: Ifosfamide 1500 mg/m2/day (50 mg/kg/day if weight is \<10 kg), IV over 6 hrs. Mesna 1500 mg/m2/day, by 24-hr IV infusion, starting with the ifosfamide infusion. Days 1-2: Carboplatin 400 mg/m2/day (13.3 mg/kg/day if weight is \<10 kg), IV over 1 hr. Days 1-5: Etoposide 100 mg/m2/day (3.3. mg/kg/day if weight is \<10 kg), IV over 2 hrs.
Study NCT04947501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Administration of CTV - cycles 1 and 4 Mesna 70 mg/kg (2100 mg/m2/day for patients >10 years old) , by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Administration of ICE - cycle 2 Mesna 1500 mg/m2/day, by 24-hr IV infusion, starting with the ifosfamide infusion.~Administration of CDV - cycle 3 Mesna 70 mg/kg ((2100 mg/m2/day for patients >10 years old), by 24-hr IV infusion, starting with the cyclophosphamide infusion.
Study NCT06174896 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group 1
Description: The LMA Proseal will be inserted directly by hand, without the use of any laryngoscope, as recommended in the instruction manual. The cuff will be gently guided along the hard palate where it is pushed into the hypopharynx and increased resistance is felt, and the cuff will be placed towards the hypopharynx.
Study NCT06174896 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group 2
Description: Appropriately sized laryngoscope blade will be used and after the location of the epiglottis is determined, the tongue and epiglottis will be lifted forward. Then, LMA Proseal will be placed at the point where resistance is felt at a level where the proximal edge of the mask can be seen.
Study NCT06174896 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group 3
Description: After the video laryngoscope is placed with an appropriately sized blade, the location of the epiglottis and vocal cords will be determined and the LMA Proseal will be placed at the point where slight resistance is encountered after the epiglottis is lifted. proximal aspect of LMA
Study NCT05705167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plitidepsin
Description: IV infusion over 60-minutes
Study NCT05920122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% Chlorhexidine gluconate with 70% alcohol
Description: Patients will be prepared similarly using the appropriate number of 26mL Chloraprep sticks for their body surface area. The lever will be pinched to activate the ampoule and release the antiseptic. The solution will be given time to partially load in the sponge. The sponge will be pressed against the skin area where the incision is intended moving back and forth for 30 sec , then working up towards the upper edge of the surgical field and then working from below the incision sight to the upper thighs. The antiseptic will be given time to dry (3 min)
Study NCT05920122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4% Chlorhexidine Gluconate aqueous solution
Description: Patients will be scrubbed preoperative with an applicator that contain 4% chlorohexidine aqueous solution (3 consecutive applications) liberally over 2 minutes followed by drying with sterile towel. The area scrubbed will be the same as the chloraprep group.
Study NCT04736056 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Therapy for Insomnia with Cognitive-Behavioral Symptom Coping Skills
Description: Mindfulness-based sleep strategies and cognitive-behavioral symptom coping skills.
Study NCT05806554 — intervention group
Intervention type: DEVICE
Intervention: Continuous glucose monitoring device
Description: Continuous glucose monitoring device
Study NCT05510687 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glasses to correct presbyopia
Description: Participants will receive eyeglasses to correct presbyopia, as per the power determined in the eye examination.
Study NCT05295225 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Green Light Emitting Diode
Description: GLED exposure for two hours
Study NCT05295225 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: White Light Emitting Diode
Description: WLED exposure for two hours
Study NCT06128551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Assigned interventions
Description: Drug: RMC-6291 and RMC-6236 Oral tablets
Study NCT03919916 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serratus plane block
Description: Placement of initial local anaesthetic bolus and catheter for continuous infusion in the plane between latissimus dorsi and serratus anterior in the midaxillary line at the level of the 5th rib
Study NCT03919916 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient controlled analgesia
Description: Computerised pump device facilitating the patient self administration and titration as needed of morphine
Study NCT03919916 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient controlled analgesia
Description: Computerised pump device facilitating the patient self administration and titration as needed of morphine
Study NCT05713227 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: White rice
Description: 185 g Jasmine (white) rice boiled in 356 g water
Study NCT05713227 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gellan gum
Description: Food grade hydrocolloid polysaccharide 5.5g dissolved in 356g cooking water containing 185g rice
Study NCT06094894 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sucralose
Description: Food additive used to replace sugar providing a sweet taste without calories.
Study NCT06094894 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Cornstarch without significant physiological effects
Study NCT04711317 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal high flow oxygen
Description: Pregnant women scheduled for cesarian section in general anaesthesia will be preoxygenated using nasal high flow oxygen
Study NCT06690567 — intervention group
Intervention type: DEVICE
Intervention: Impella implantation
Description: To implante Impella
Study NCT06690671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golidocitinib in combination with anti-PD-1
Description: Golidocitinib 150/75 mg once daily (QD) with anti-PD-1 （200 mg IV Q3W），21 days in one cycle.
Study NCT06257420 — intervention group
Intervention type: DRUG
Intervention: Rapamycin
Description: Once weekly oral rapamycin
Study NCT05696522 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy
Description: Stereotactic ablative radiotherapy will be delivered to a volume of ventricular myocardium responsible for the clinical ventricular tachycardia.
Study NCT05705791 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QuiremSpheres
Description: 166Holmium selective internal intra-arterial radiation therapy at C1D15 of the Atezolizumab and Bevacizumab therapy
Study NCT05777694 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patients who underwent cesarean section under spinal anesthesia with 25 gauge spinal needle
Description: the investigators performed spinal anesthesia with 25 gauge pencil point spinal needle to that patient group for prevent postdural puncture headache
Study NCT05777694 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patients who underwent cesarean section under spinal anesthesia with 26 gauge spinal needle
Description: the investigators performed spinal anesthesia with 26 gauge pencil point spinal needle to that patient group for prevent postdural puncture headache
Study NCT05777694 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patients who underwent cesarean section operation under spinal anesthesia with 27 gauge spinal needle
Description: the investigators performed spinal anesthesia with 27 gauge pencil point spinal needle to that patient group for prevent postdural puncture headache
Study NCT05347394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-708
Description: Solution or suspension for oral administration.
Study NCT05347394 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to VX-708 for oral administration.
Study NCT05324137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM326
Description: CM326 injection
Study NCT06030427 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Dietary Intervention
Description: Participate in weight management program
Study NCT06030427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive patient education handouts
Study NCT05324137 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo